This assertion is supported by the work of Kum et al. (Qinghua et al., 2024), which demonstrates that the inhibition of SP1 activity at the DNA level is an effective approach for the treatment of lung fibrosis. This evidence concerns the gene SP1 and pulmonary fibrosis.